Instil Bio, Inc.
TILHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeInstil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. Valued at $39.6M, TIL is a micro-cap name in its sector. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
Market Cap
$39.6M
Beta
1.94
P/E (TTM)
—
P/E (Fwd)
-0.40
EPS (TTM)
$-4.43
EPS (Fwd)
$-14.64
ROE
-25.3%
ROA
-10.8%
Cash
$69.7M
Total Debt
$87.4M
Free CF
$81.8M
52W Change
-70.6%
Annual Financials
Cash vs Debt
Where TIL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TIL finished 24.61% below its 150-day moving average ($7.68) and 25.48% below its 200-day moving average ($7.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TIL overbought or oversold?
At the October 20, 2026 close, TIL's RSI(14) was 20.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $69.7M in cash, though total debt stands at $87.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $81.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -25.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, TIL tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing TIL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.